Advocacy intelligence hub — real-time data for patient organizations
Bayer
NYU Langone Health — NA
China National Center for Cardiovascular Diseases — PHASE4
Ospedali Riuniti Trieste
Hospices Civils de Lyon
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Actemra
(tocilizumab)Orphan drugstandardGenentech, Inc.
Interleukin-6 Receptor Antagonist [EPC]
12.1 Mechanism of Action Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-m...
ILARIS
(canakinumab)Orphan drugstandardNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutr...
Browse all Systemic-onset juvenile idiopathic arthritis news →
Takahiro Kakehi
Chugai Pharmaceutical
Brian Jamieson, MD, dds
Swedish Orphan Biovitrum
📍 MARYSVILLE, WA
Pierre Quartier-dit-Maire, MD
Pediatric Immuno-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, 149 rue de Sevre, 75015 Paris, France
Nemanja Damjanov, MD, PhD
Institute of Rheumatology Belgrade
Norman T. Ilowite, MD
Montefiore Medical Center
Monique Hinchcliff, MD, MD, MS
Yale University
📍 NORTH HAVEN, CT
View all Systemic-onset juvenile idiopathic arthritis specialists →